ArticleJournal of medical case reports2026
Epstein-Barr virus-positive small cell neuroendocrine carcinoma of the nasopharynx: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroudSmall cell neuroendocrine carcinoma is a rare occurrence in the nasopharynx, characterized by aggressiveness and poor prognosis, with clinical and pathological features that remain incompletely understood. CASE PRESENTATION: We present a case of Epstein-Barr virus-positive nasopharyngeal small cell neuroendocrine carcinoma of a 58-year-old Chinese man who initially presented with symptoms of left ear tightness and aural fullness. The patient underwent three cycles of induction therapy comprising chemotherapy (cisplatin-etoposide) in conjunction with immune checkpoint inhibitors (adebrelimab), followed by concurrent chemoradiotherapy (triweekly cisplatin and a total dose of 68 Gy delivered in 31 fractions). Subsequent radiological evaluation revealed a complete response post-treatment at 6 months, with no evidence of recurrence or metastasis at the 6-month follow-up.
conclusionManaging nasopharyngeal small cell neuroendocrine carcinoma poses challenges due to its rarity. Treatment modalities encompass surgery, radiotherapy, concurrent chemoradiotherapy, and chemotherapy alone. Novel therapeutic strategies, such as immune checkpoint inhibitors, may offer promising options for advancing treatment modalities. Further clinical data on similar cases are warranted to enhance treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.